▁In 10.375
▁a 6.50390625
▁prom 8.65625
ising 1.787109375
▁development 4.5546875
▁in 2.904296875
▁the 1.982421875
▁field 4.2265625
▁of 0.38818359375
▁on 4.55078125
col 0.0288848876953125
ogy 0.10986328125
, 1.451171875
▁the 2.25390625
▁British 8.1015625
▁bi 8.40625
ote 2.56640625
chn 1.015625
ology 0.1722412109375
▁firm 3.619140625
, 2.5078125
▁British 5.40625
▁Bi 5.31640625
ote 0.051483154296875
ch 3.24609375
, 3.0546875
▁has 3.40625
▁announced 3.775390625
▁that 1.4951171875
▁its 2.890625
▁ground 5.21484375
bre 2.14453125
aking 0.00574493408203125
▁anti 5.109375
- 0.44775390625
can 1.4833984375
cer 0.043304443359375
▁treatment 2.240234375
, 1.728515625
▁Mar 8.28125
im 8.921875
ast 10.015625
at 5.64453125
, 0.8818359375
▁will 3.076171875
▁be 0.9130859375
▁put 4.85546875
▁under 4.984375
▁scr 6.37890625
ut 0.0034885406494140625
iny 0.37890625
▁at 3.7734375
▁the 1.08984375
▁annual 4.02734375
▁European 5.16015625
▁Society 2.28515625
▁for 2.43359375
▁Medical 3.162109375
▁On 3.958984375
col 0.294677734375
ogy 0.6142578125
▁( 3.466796875
ES 5.14453125
MO 1.2861328125
) 0.8603515625
▁conference 2.78515625
▁in 1.15625
▁Vienna 3.97265625
. 1.7666015625
▁This 3.271484375
▁highly 6.0625
▁anticip 1.9990234375
ated 0.005218505859375
▁conference 1.701171875
▁will 1.2587890625
▁bring 2.3125
▁together 0.1966552734375
▁leading 2.958984375
▁exper 1.146484375
ts 0.0003235340118408203
▁and 1.9072265625
▁research 1.8837890625
ers 0.058624267578125
▁in 1.5400390625
▁on 2.861328125
col 0.0201873779296875
ogy 0.005397796630859375
▁to 2.615234375
▁evaluate 5.3125
▁the 0.751953125
▁latest 1.076171875
▁adv 2.29296875
anc 1.16015625
ements 0.00023698806762695312
▁in 0.288818359375
▁the 1.2685546875
▁field 1.1923828125
. 1.388671875
<0x0A> 1.0361328125
Mar 5.0625
im 0.406005859375
ast 0.062286376953125
at 0.0100250244140625
, 1.640625
▁a 1.0185546875
▁novel 2.31640625
▁th 4.24609375
era 0.014739990234375
pe 0.0006647109985351562
ut 0.00010883808135986328
ic 0.0078125
▁agent 2.23046875
, 1.47265625
▁is 0.93359375
▁designed 2.1328125
▁to 0.07440185546875
▁in 3.373046875
hib 0.0207977294921875
it 0.0025386810302734375
▁the 0.796875
▁activity 2.37890625
▁of 0.0203399658203125
▁matrix 6.80859375
▁metal 0.0182342529296875
lo 0.0010480880737304688
prote 0.0109100341796875
in 0.12103271484375
ases 0.51220703125
▁( 0.330078125
M 0.032989501953125
MP 0.0030574798583984375
s 0.2049560546875
), 0.75048828125
▁which 1.1630859375
▁play 1.9296875
▁a 0.45556640625
▁critical 1.5185546875
▁role 0.0120849609375
▁in 0.01018524169921875
▁tum 2.22265625
or 0.2298583984375
▁invasion 2.08984375
▁and 0.434326171875
▁met 0.195068359375
ast 0.0001863241195678711
asis 0.0443115234375
. 0.27197265625
▁By 3.361328125
▁target 2.08203125
ing 0.0016489028930664062
▁this 2.9140625
▁key 2.41015625
▁mechanism 3.390625
, 0.61376953125
▁Mar 0.369384765625
im 0.0036067962646484375
ast 0.004848480224609375
at 0.001010894775390625
▁a 3.45703125
ims 0.0196990966796875
▁to 0.00786590576171875
▁restrict 6.75
▁the 0.853515625
▁spread 1.52734375
▁of 0.15380859375
▁cancer 0.5205078125
▁cells 0.65478515625
, 1.7138671875
▁ultimately 3.974609375
▁providing 3.833984375
▁better 5.25390625
▁treatment 1.568359375
▁out 1.486328125
comes 0.00020766258239746094
▁for 0.53857421875
▁patients 0.472412109375
▁batt 4.765625
ling 0.0002486705780029297
▁various 3.140625
▁forms 1.3798828125
▁of 0.005828857421875
▁cancer 0.168212890625
. 0.11859130859375
<0x0A> 0.441162109375
The 1.8623046875
▁ES 4.14453125
MO 0.01493072509765625
▁conference 0.96044921875
▁will 0.7880859375
▁provide 2.01171875
▁an 1.0869140625
▁ideal 1.2138671875
▁platform 0.8076171875
▁for 0.327880859375
▁British 9.3515625
▁Bi 2.09375
ote 0.003795623779296875
ch 1.3486328125
▁to 0.26416015625
▁present 1.94921875
▁their 3.390625
▁research 3.51171875
▁find 1.4072265625
ings 9.417533874511719e-06
▁and 1.1083984375
▁eng 4.78125
age 0.00852203369140625
▁in 1.208984375
▁meaning 2.216796875
ful 0.00010251998901367188
▁discuss 0.84912109375
ions 2.6345252990722656e-05
▁with 0.1431884765625
▁on 4.00390625
col 0.450439453125
ogy 0.0001823902130126953
▁exper 0.62353515625
ts 6.9141387939453125e-06
▁from 1.1455078125
▁around 0.4697265625
▁the 0.0010051727294921875
▁world 0.2208251953125
. 0.1844482421875
▁This 2.416015625
▁opportunity 3.900390625
▁will 0.525390625
▁not 3.603515625
▁only 0.0523681640625
▁allow 1.861328125
▁them 2.611328125
▁to 0.016326904296875
▁show 2.3515625
case 0.01104736328125
▁the 1.17578125
▁potential 2.77734375
▁of 0.334716796875
▁Mar 0.8564453125
im 0.0018873214721679688
ast 0.00336456298828125
at 0.000431060791015625
▁but 2.943359375
▁also 0.262451171875
▁receive 6.23828125
▁valuable 0.7236328125
▁feedback 0.2178955078125
▁and 1.57421875
▁ins 1.9609375
ights 0.00046443939208984375
▁from 0.69775390625
▁the 1.9638671875
▁global 2.595703125
▁medical 1.86328125
▁community 0.129638671875
. 0.2215576171875
<0x0A> 0.21484375
The 1.99609375
▁potential 5.9609375
▁of 0.4716796875
▁Mar 0.1710205078125
im 0.0012159347534179688
ast 0.00225067138671875
at 0.0008044242858886719
▁has 2.298828125
▁been 0.6025390625
▁demonstrated 2.232421875
▁in 0.63330078125
▁pre 2.294921875
cl 0.2479248046875
in 1.537799835205078e-05
ical 0.00027060508728027344
▁studies 0.395751953125
, 0.76416015625
▁exhib 9.328125
iting 0.007091522216796875
▁prom 1.9306640625
ising 0.0003008842468261719
▁results 0.62109375
▁in 0.4404296875
▁in 2.05859375
hib 0.0210418701171875
iting 0.01259613037109375
▁tum 1.87890625
or 0.0311279296875
▁growth 0.6455078125
▁and 0.52490234375
▁mit 6.91015625
ig 0.1080322265625
ating 0.00255584716796875
▁cancer 2.599609375
▁cell 1.5380859375
▁invas 3.05859375
iveness 0.09698486328125
. 0.157470703125
▁These 2.904296875
▁pre 2.92578125
cl 0.3115234375
in 1.5139579772949219e-05
ical 0.0005822181701660156
▁find 1.3984375
ings 8.344650268554688e-07
▁have 0.595703125
▁p 3.96484375
aved 0.00298309326171875
▁the 0.01470184326171875
▁way 0.02105712890625
▁for 0.06512451171875
▁further 2.09375
▁investig 3.298828125
ations 0.03302001953125
▁in 2.0703125
▁clin 2.34375
ical 0.006061553955078125
▁tri 0.30615234375
als 1.2040138244628906e-05
, 1.001953125
▁target 5.83203125
ing 0.0201416015625
▁specific 3.0546875
▁cancer 1.931640625
▁types 0.578125
. 1.6640625
<0x0A> 0.541015625
D 5.19140625
uring 0.438720703125
▁the 0.25732421875
▁conference 1.1259765625
, 0.033172607421875
▁British 0.11688232421875
▁Bi 0.006107330322265625
ote 0.002010345458984375
ch 0.00595855712890625
▁will 0.13525390625
▁discuss 4.015625
▁the 0.74658203125
▁pre 3.087890625
lim 2.2265625
inary 0.0005331039428710938
▁results 0.69677734375
▁of 0.32421875
▁their 0.931640625
▁Ph 2.24609375
ase 0.0023059844970703125
▁II 2.890625
▁clin 1.0517578125
ical 0.0002779960632324219
▁trial 0.279296875
, 1.193359375
▁which 0.80810546875
▁focus 6.37109375
es 0.01107025146484375
▁on 0.006427764892578125
▁evalu 1.1591796875
ating 0.00012159347534179688
▁the 0.145263671875
▁safety 1.0146484375
▁and 0.2005615234375
▁effic 0.2315673828125
acy 1.0609626770019531e-05
▁of 0.01380157470703125
▁Mar 0.127685546875
im 0.000736236572265625
ast 0.00220489501953125
at 0.0015621185302734375
▁in 0.222412109375
▁patients 1.220703125
▁with 0.281982421875
▁advanced 1.3056640625
▁breast 3.828125
▁cancer 0.04339599609375
. 0.2049560546875
▁This 1.9853515625
▁trial 1.0869140625
▁a 2.69921875
ims 2.1696090698242188e-05
▁to 0.0028209686279296875
▁determine 1.8359375
▁the 0.765625
▁drug 4.83203125
' 0.006011962890625
s 0.00041222572326660156
▁ability 1.630859375
▁to 0.00860595703125
▁restrict 6.42578125
▁tum 1.677734375
or 0.018798828125
▁pro 2.814453125
gression 0.1680908203125
▁and 0.4892578125
▁improve 2.169921875
▁patient 1.919921875
▁out 0.69580078125
comes 0.018463134765625
. 0.2496337890625
▁If 4.69921875
▁the 1.236328125
▁results 0.73583984375
▁prove 4.67578125
▁successful 1.81640625
, 0.01512908935546875
▁the 1.6884765625
▁potential 4.625
▁imp 6.4453125
lications 0.043426513671875
▁for 1.1748046875
▁breast 3.77734375
▁cancer 0.005115509033203125
▁treatment 1.4677734375
▁could 1.7939453125
▁be 0.13330078125
▁significant 0.90869140625
. 0.1949462890625
<0x0A> 0.11651611328125
B 2.208984375
ey 6.54296875
ond 0.001041412353515625
▁breast 3.533203125
▁cancer 0.00778961181640625
, 0.14892578125
▁the 2.32421875
▁potential 1.291015625
▁for 3.34765625
▁Mar 0.1656494140625
im 0.0003829002380371094
ast 0.0014934539794921875
at 0.0005350112915039062
▁to 1.6796875
▁be 2.076171875
▁effective 2.83984375
▁in 0.1646728515625
▁other 1.4248046875
▁cancer 2.072265625
▁types 0.0604248046875
▁will 3.208984375
▁also 1.0908203125
▁be 0.006389617919921875
▁expl 1.4765625
ored 9.179115295410156e-06
▁at 1.5810546875
▁the 0.1318359375
▁conference 0.26513671875
. 0.0767822265625
▁British 1.3896484375
▁Bi 0.0026607513427734375
ote 0.0007376670837402344
ch 0.0029621124267578125
▁has 2.267578125
▁initi 5.3046875
ated 0.0009908676147460938
▁pre 1.7158203125
cl 0.03961181640625
in 1.4543533325195312e-05
ical 0.00010073184967041016
▁studies 0.343017578125
▁to 1.3212890625
▁evaluate 1.02734375
▁the 0.244384765625
▁drug 0.9228515625
' 0.1053466796875
s 0.0006055831909179688
▁effic 1.5693359375
acy 4.5299530029296875e-06
▁in 0.2032470703125
▁lung 4.31640625
, 1.7822265625
▁pan 2.390625
cre 8.189678192138672e-05
atic 0.083251953125
, 0.1243896484375
▁and 0.83349609375
▁col 2.015625
ore 0.0021762847900390625
ct 1.9550323486328125e-05
al 0.0004677772521972656
▁can 1.052734375
cers 2.1696090698242188e-05
. 0.44775390625
▁These 1.3623046875
▁on 4.078125
going 0.02203369140625
▁studies 0.5625
▁show 5.8671875
▁promise 0.60498046875
▁and 2.794921875
▁raise 6.4765625
▁hopes 3.064453125
▁of 2.517578125
▁a 1.6015625
▁break 2.591796875
through 0.000926971435546875
▁in 0.4541015625
▁tre 2.63671875
ating 5.1140785217285156e-05
▁various 2.173828125
▁challeng 9.609375
ing 0.1580810546875
▁forms 1.5244140625
▁of 0.0011157989501953125
▁cancer 0.032745361328125
. 0.11053466796875
<0x0A> 0.12939453125
Wh 3.978515625
ile 0.061187744140625
▁significant 5.9296875
▁progress 0.63134765625
▁has 0.08966064453125
▁been 0.1029052734375
▁made 0.0330810546875
▁in 0.256591796875
▁the 0.90771484375
▁fight 2.404296875
▁against 0.01171875
▁cancer 0.0732421875
, 0.08721923828125
▁there 0.7666015625
▁is 0.52587890625
▁still 0.1434326171875
▁a 0.9755859375
▁long 0.4443359375
▁way 0.15283203125
▁to 0.006557464599609375
▁go 0.002166748046875
. 0.481201171875
▁Medical 6.03125
▁profession 2.341796875
als 1.0967254638671875e-05
▁and 1.1533203125
▁research 0.73828125
ers 0.0088043212890625
▁are 1.490234375
▁constantly 1.638671875
▁expl 2.7890625
oring 6.377696990966797e-05
▁new 0.327880859375
▁a 1.9853515625
ven 0.00027060508728027344
ues 0.00011026859283447266
▁and 2.1640625
▁innov 2.390625
ative 0.2154541015625
▁treat 2.27734375
ments 7.176399230957031e-05
▁to 0.53759765625
▁improve 1.66015625
▁patient 1.16015625
▁out 0.07415771484375
comes 0.0011539459228515625
. 0.360595703125
▁Mar 2.564453125
im 0.0012969970703125
ast 0.0013580322265625
at 0.00030875205993652344
' 3.91015625
s 0.0007991790771484375
▁appearance 9.65625
▁at 0.1024169921875
▁the 0.1812744140625
▁ES 0.57861328125
MO 0.0029201507568359375
▁conference 0.11480712890625
▁sign 6.44921875
ifies 0.0009264945983886719
▁a 1.482421875
▁critical 4.15625
▁step 1.216796875
▁in 0.7275390625
▁this 2.345703125
▁journey 1.0888671875
, 1.3564453125
▁as 2.11328125
▁it 0.52099609375
▁highlight 3.80078125
s 0.0002543926239013672
▁the 0.259521484375
▁potential 0.71240234375
▁of 0.205322265625
▁target 5.14453125
ed 1.740234375
▁th 3.1015625
era 0.00010979175567626953
pe 1.621246337890625e-05
ut 1.728534698486328e-05
ic 2.521484375
▁approaches 4.4765625
▁in 1.41015625
▁comb 2.890625
ating 0.367431640625
▁cancer 0.36474609375
. 0.11651611328125
<0x0A> 0.61572265625
With 3.431640625
▁the 0.9775390625
▁presentation 6.87890625
▁and 3.77734375
▁review 5.48828125
▁of 0.041046142578125
▁Mar 3.01171875
im 0.0010318756103515625
ast 0.0030879974365234375
at 0.0033855438232421875
▁at 1.5810546875
▁the 0.175048828125
▁ES 0.69921875
MO 0.0014085769653320312
▁conference 0.07818603515625
, 0.11029052734375
▁the 2.599609375
▁medical 3.28515625
▁community 0.12432861328125
▁eager 10.21875
ly 0.01556396484375
▁a 0.048828125
wa 0.00014829635620117188
its 2.181529998779297e-05
▁the 0.5869140625
▁results 1.5654296875
▁of 0.6787109375
▁the 1.1796875
▁Ph 3.162109375
ase 0.0012111663818359375
▁II 0.1968994140625
▁clin 0.2081298828125
ical 0.0005006790161132812
▁trial 0.0308837890625
▁and 1.4951171875
▁the 1.6298828125
▁further 3.30859375
▁expl 2.365234375
oration 0.03619384765625
▁of 0.034210205078125
▁its 1.412109375
▁effic 2.482421875
acy 1.7523765563964844e-05
▁in 0.1717529296875
▁various 3.220703125
▁cancer 0.7900390625
▁types 0.02490234375
. 0.031982421875
▁The 2.17578125
▁enthus 6.52734375
ias 0.1380615234375
m 7.832050323486328e-05
▁surrounding 1.7509765625
▁this 1.162109375
▁novel 2.58984375
▁anti 4.54296875
- 0.00452423095703125
can 0.04388427734375
cer 0.0008764266967773438
▁treatment 0.5146484375
▁exempl 6.2890625
ifies 0.0008230209350585938
▁the 0.1827392578125
▁rel 8.0625
ent 0.00041365623474121094
less 0.0002722740173339844
▁efforts 1.212890625
▁made 3.111328125
▁by 0.2230224609375
▁British 0.41943359375
▁Bi 0.003864288330078125
ote 0.0008444786071777344
ch 0.0023479461669921875
▁and 2.546875
▁the 1.1591796875
▁wider 5.19140625
▁scientific 2.05078125
▁community 0.0283660888671875
▁to 0.3291015625
▁bring 2.296875
▁en 8.765625
hanced 0.07525634765625
▁treatment 1.2451171875
▁options 0.1937255859375
▁to 0.1361083984375
▁patients 0.771484375
▁batt 0.58203125
ling 0.00030040740966796875
▁cancer 0.759765625
. 0.0472412109375
